Skip to main content
. 2013 Dec 9;8(12):e81348. doi: 10.1371/journal.pone.0081348

Figure 4. SPAG9 Immunoreactivity score (IRS) in different tumor stages and grades of bladder TCC patients.

Figure 4

(A) SPAG9 IRS in superficial non-muscle invasive tumors and in muscle-invasive tumors revealed significant difference (P<0.012). (B) As depicted in histograph, analysis of SPAG9 expression, amongst superficial non-muscle invasive tumor patients was found to be significantly different (P<0.001) in SPAG9 IRS group I (>60% SPAG9 positive cells; n = 35 of 56) and SPAG9 IRS group II (<60% SPAG9 positive cells; n = 21 of 56). (C) Muscle invasive tumor patients, a significant difference (P<0.001) of SPAG9 IRS was observed in the two groups: SPAG9 IRS group I (>60% SPAG9 positive cells; n = 19 of 45) and SPAG9 IRS group II (<60% SPAG9 positive cells; n = 26 of 45) as shown in histograph. (D) There was significant difference in SPAG9 IRS in low and high grade tumor tissue specimens (P<0.001). (E) As shown in histograph, analysis of SPAG9 expression within low grade tumors grade significant difference (P<0.001) was found between SPAG9 IRS group I (>60% SPAG9 positive cells; n = 29 of 40) and SPAG9 IRS group II (<60% SPAG9 positive cells; n = 11 of 40). (F) As shown in histograph, SPAG9 expression was found to be significantly different (P<0.001) within high grade tumor patients between SPAG9 IRS group I (>60% SPAG9 positive cells; n = 25 of 61) and SPAG9 IRS group II (<60% SPAG9 positive cells; n = 36 of 61). Point indicates mean; bar, standard error.